1.
J. investig. allergol. clin. immunol
; 32(1): 66-68, 2022. tab
Article
in English
| IBECS
| ID: ibc-203892
2.
J Investig Allergol Clin Immunol
; 32(1): 66-68, 2021 Feb 21.
Article
in English
| MEDLINE
| ID: mdl-34014167
3.
J Investig Allergol Clin Immunol
; 31(3): 265-267, 2021 Jun 22.
Article
in English
| MEDLINE
| ID: mdl-32856592
Subject(s)
Adenocarcinoma/drug therapy , Anaphylaxis/prevention & control , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Bevacizumab/therapeutic use , Desensitization, Immunologic/methods , Drug Hypersensitivity/therapy , Drug-Related Side Effects and Adverse Reactions/prevention & control , Lung Neoplasms/drug therapy , Adenocarcinoma/complications , Anaphylaxis/etiology , Antibodies, Monoclonal, Humanized/adverse effects , Antineoplastic Agents, Immunological/adverse effects , Bevacizumab/adverse effects , Drug Hypersensitivity/complications , Humans , Lung Neoplasms/complications , Male , Middle Aged , Severity of Illness Index , Treatment Outcome
4.
J. investig. allergol. clin. immunol
; 31(3): 265-267, 2021. tab
Article
in English
| IBECS
| ID: ibc-215213
Subject(s)
Humans , Male , Middle Aged , Adenocarcinoma/drug therapy , Anaphylaxis/prevention & control , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents/therapeutic use , Bevacizumab/therapeutic use , Desensitization, Immunologic/methods , Lung Neoplasms/drug therapy , Anaphylaxis/chemically induced , Antibodies, Monoclonal, Humanized/adverse effects , Drug Hypersensitivity/therapy , Antineoplastic Agents/adverse effects , Bevacizumab/adverse effects , Severity of Illness Index , Treatment Outcome
5.
J Investig Allergol Clin Immunol
; 30(5): 376-377, 2020.
Article
in English
| MEDLINE
| ID: mdl-32376514